MONIQUE ALLMAN: Open Payments
NPI 1659605723 · KATY, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,034 in 38 payments from 14 companies in 2025. Trend: 2023 $5,001 · 2024 $1,968 · 2025 $2,034
Food & beverage: $1,981Education: $53
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $688 |
| GlaxoSmithKline, LLC. | 6 | $185 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $173 |
| GENZYME CORPORATION | 2 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $162 |
| Incyte Corporation | 1 | $142 |
| Eisai Inc. | 1 | $124 |
| Galderma Laboratories, L.P. | 1 | $116 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $82 |
| Pharming Healthcare, Inc. | 2 | $57 |
Products named: NEFFY, CUVITRU, NUCALA, WAYRILZ, Leqembi, NEMLUVIO, DUPIXENT, Kerendia.
Industry payments across TX — which companies pay providers there.
